Optimizing Image Cytometry and HCA for Early Cell Health and Cytotoxicity Assessment

  • Poster by GE Healthcare presented at Miptec 2012Poster by GE Healthcare presented at Miptec 2012
  • Emerging image cytometry and high content analysis (HCA) technologies offer a number of clear advantages in monitoring cell health and quantifying the effects of test substances.

• Enable quantification of effects in situ and in-context in a non-disruptive, non-destructive fashion. The extraction of multi-parametric data on a cell-by-cell basis enables dynamic and detailed profiling of cell phenotypes. Phenotypic profiling has the potential to aid in the identification of toxic compounds earlier in the drug discovery process and to provide valuable insight into mechanisms of toxicity.

  • Current reagent formulations available for cell health assays are not always fully optimised or validated for the needs of the user, and frequently under-utilise some of the features and advantages that imaging platforms offer. To this end we have developed Cytiva Cell Health Assay for HCA (Product Code: 29024468) and Cytiva Cell Integrity for HCA (Product Code: 29027502) which offer several benefits to the end user

• Assessments of cell viability (live/dead assays) and mitochondrial function are often performed separately, but can be interrogated from the same image by combining the membrane integrity indicator (Reagent B) with the mitochondrial status indicator (Reagent C). This allows for faster plate scans or the repurposing of the Cy5 channel with another parameter depending on user preference.
• Another benefit of optimisation is the adoption of a more sensitive dye for measuring intracellular calcium (Reagent D). This offers the potential of capturing stress induced changes to calcium levels at lower doses than is currently enabled by the most commonly used dye, Fluo-4-AM.

  • Together with these changes to the dye reagents we will demonstrate the prime importance of utilising more relevant cell models such as human embryonic stem cell derived cardiomyocytes.

Take a look at the poster (pdf).

Authors:
Gareth Phillips, Angela Williams, Liz Price, Michael Clements, Hayley Tinkler, Ray Ismail, Alla Zaltsman, Jeanette George, Liz Roquemore.
GE Healthcare, Amersham Place, Little Chalfont, Buckinghamshire, England, UK HP7 9NA.

Contact

GE Healthcare
Amersham Place, Bucks. 0
Little Chalfont, HP7 9NA
United Kingdom
Phone: +44 1494 542626
Telefax: +44 1494 542160

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.